Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

May 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-05-18

Reporting Person: Dunlop A. Sinclair (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-18	Common Stock	S	64179	$51.66	Disposed	110549	Indirect
2021-05-18	Common Stock	S	14216	$52.63	Disposed	96333	Indirect
2021-05-18	Common Stock	S	36387	$53.78	Disposed	59946	Indirect
2021-05-18	Common Stock	S	22318	$54.57	Disposed	37628	Indirect
2021-05-18	Common Stock	S	1200	$52.01	Disposed	319479	Indirect
2021-05-18	Common Stock	S	10388	$53.50	Disposed	309091	Indirect
2021-05-18	Common Stock	S	800	$54.02	Disposed	308291	Indirect
2021-05-19	Common Stock	S	7612	$50.00	Disposed	300679	Indirect
2021-05-20	Common Stock	S	5773	$48.10	Disposed	31855	Indirect

Footnotes

F1: The reported transaction involved a sale of shares held by MASA Life Science Ventures, LP ("MASA"). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.16 to $52.15. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) to this Form 4.

F2: The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.16 to $53.12.

F3: The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $54.15.

F4: The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.16 to $54.94.

F5: The reported transaction involved a sale of shares held by Epidarex Capital I, LP ("Epidarex"). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.00 to $52.03. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (7) to this Form 4.

F6: The reported transaction involved a sale of shares held by Epidarex. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.00 to $53.99.

F7: The reported transaction involved a sale of shares held by Epidarex. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.00 to $54.04.

F8: The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.00 to $48.50.

F9: The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.

F10: The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.